Emerging advanced therapies for feline CKD including stem cell treatment, novel phosphate binders, and anti-fibrotic agents offer new welfare-preserving options for affected cats.
The expanding therapeutic landscape for feline CKD represents genuine welfare progress — not just marginal improvements but meaningful extensions of good-quality life for cats with this common condition. Each therapeutic advance addresses a specific welfare burden: appetite stimulants target the nausea that makes daily existence miserable, novel phosphate binders improve compliance with dietary restriction, and anti-fibrotic approaches may slow the underlying disease trajectory. The welfare impact is measured not in survival statistics but in quality-of-life indicators: is the cat eating, grooming, seeking interaction, and experiencing positive states? Advanced therapy selection should be guided by these welfare outcomes rather than biochemical targets alone.